Scientific papers rarely stand alone. A finding may depend on earlier work, inspire later experiments, conflict with another study, attract funding, or quietly disappear after a retraction. Yet researchers often encounter those relationships through separate searches, incomplete citation trails and databases that were not designed to show the whole neighborhood around a claim.
On September 24, 2026, the National Institutes of Health launched Linked Discoveries, an experimental tool developed by the National Library of Medicine. From a PubMed citation, researchers can explore a network of related publications, citation links, reviews, retractions, NIH funding and shared conditions, genes and chemicals. NIH says the first version represents more than 29 million PubMed publications. (National Institutes of Health launch announcement)
The tool addresses a genuine problem. It does not solve it.
A map is not a verdict
NIH describes Linked Discoveries as part of its agency-wide effort to strengthen replication and reproducibility in biomedical research. The tool uses an AI-informed approach to identify related publications and presents them through graph and timeline views. Researchers can narrow a research neighborhood by conditions, genes and chemicals, then inspect associated reviews, retractions and funding information.
That may make scientific context easier to find. It does not tell researchers whether a study is correct.
NIH explicitly says Linked Discoveries does not judge study quality or determine whether a finding has been successfully replicated. The system organizes relationships among publications and leaves the evaluation of evidence to researchers. The accompanying National Library of Medicine user guide also describes the resource as an early-stage pilot whose results may be incomplete or inaccurate.
This is not a minor disclaimer. It defines what the tool is.
A paper surrounded by hundreds of related publications is not necessarily more reliable than an isolated paper. It may be influential, controversial, methodologically useful or simply old enough to have accumulated citations. Conversely, an important study may be poorly connected because later researchers use different terminology, fail to cite it, publish in less visible journals or report a negative result that attracts little attention.
Visibility and validity are related, but they are not interchangeable.
The evidence network can be incomplete
Research on citation networks illustrates the problem. A study examining 259 meta-analyses involving 2,413 randomized clinical trials found that only 46 percent of the trial networks formed a single connected citation group. The remaining networks contained disconnected groups of studies. The authors concluded that citation networks could help identify evidence but could not reliably replace systematic searching. (Citation networks of related trials study)
Linked Discoveries is more ambitious than simply following references. It combines citation information with related-article methods and other biomedical metadata. But the underlying warning remains: a connected literature is not necessarily a complete literature.
That matters especially for replication. A study that appears in the same neighborhood as an earlier paper may test the same question under different conditions. A failed reproduction may indicate a false original result, a context-dependent effect, a difference in implementation, inadequate statistical power or a problem in the follow-up study. “Replication” is not a single scientific category with a simple yes-or-no meaning.
A visualization that collapses those distinctions could create a new kind of false confidence. It might make a field look better organized without making its evidence more dependable.
Better discovery still has value
These limitations are not an argument against Linked Discoveries. They are an argument for using it as a research aid rather than a scientific referee.
Researchers often need to know more than whether a paper contains a particular keyword. They may want to see what came before a result, which groups examined it later, whether a related article was retracted, whether the finding attracted independent funding or whether the apparent consensus rests on a small number of highly connected papers.
Linked Discoveries may be especially useful at the beginning of an investigation. It can help a researcher identify questions that deserve closer reading: Why do two papers use the same gene but reach different conclusions? Are later studies direct replications or merely related experiments? Does a widely cited finding have supporting evidence outside its original research group? Are negative or contradictory studies present but less visible?
Those are valuable questions. The tool cannot answer them by itself.
NIH is changing more than a search interface
The broader initiative is institutional. NIH has said that replication and reproducibility should be embedded across the biomedical research enterprise through independent replication studies, data and software sharing, incentives for rigorous work, training and supporting infrastructure. Its Replication and Reproducibility Initiative treats reliability as a responsibility shared by researchers, funders, institutions, journals and reviewers.
That approach recognizes a problem that is often described too narrowly. Scientific reliability depends not only on whether an individual experiment was conducted carefully. It also depends on which findings are rewarded, which studies are visible, whether negative results can be found, whether data and code are available, and whether researchers receive credit for validation and correction rather than novelty alone.
In a June 2026 request for information, NIH questioned whether publication counts and citation metrics adequately measure scientific contribution. The agency sought alternatives that would recognize replication, data sharing, collaboration, mentorship, foundational work and public impact. (NIH request for information on measuring and rewarding scientific impact)
Linked Discoveries fits that institutional project. It attempts to improve the information environment in which biomedical claims are discovered and assessed. That is more consequential than adding another search feature, but it also raises a higher standard for evaluation.
What NIH should measure next
The launch demonstrates that the tool exists and that it can display relationships across a large body of PubMed records. It does not yet demonstrate that researchers will find more overlooked replications, that systematic reviews will become more complete or that clinical decisions will improve.
Those effects are testable. NIH should eventually publish evidence about how often the system surfaces known replication studies, how frequently its “related” links are judged useful by experts and what kinds of literature it misses. It should explain how the system handles contradictory findings, direct versus conceptual replication, preprints, non-PubMed publications and unpublished results. It should also make clear why two papers were linked, rather than presenting the connection as self-explanatory.
The most important test may be whether the tool exposes inconvenient evidence. A map that mainly reinforces highly cited papers and familiar research communities would be easier to use without being much more informative. A useful system should make it harder to mistake prominence for support.
The literature is not the biology
Biomedical researchers ultimately study bodies, diseases, treatments and biological processes. A map of publications remains a map of what researchers published and what databases indexed. It does not directly measure whether a drug works, whether a mechanism exists or whether a patient will benefit.
That distinction is easy to lose when a complex interface produces an attractive network of evidence. The network can show what is connected. It cannot establish why the connection matters.
NIH has taken a sensible approach by building a tool that assists judgment rather than claiming to automate it. The agency is also correct that modern biomedical research needs better ways to locate context. But the value of Linked Discoveries will depend on whether researchers use its connections as prompts for scrutiny rather than as substitutes for scrutiny.
A map can make the evidence easier to inspect. It cannot do the inspecting for us.
